April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
Pharmacokinetic Study of Vitreous and Serum Concentrations of Triamcinolone Acetonide After Posterior Sub-Tenon’s Injection
Author Affiliations & Notes
  • K. D. Kovacs
    Ophthalmology, Beth Israel Deaconess Medical Center, Boston, Massachusetts
  • M. T. Quirk
    Ophthalmology, Beth Israel Deaconess Medical Center, Boston, Massachusetts
  • O. M. Ceron
    Ophthalmology, Beth Israel Deaconess Medical Center, Boston, Massachusetts
  • P. S. Silva
    Beetham Eye Institute, Joslin Diabetes Center, Boston, Massachusetts
  • R. J. Singh
    Dept of Laboratory Medicine and Pathology, Division of Clinical Biochemistry, Mayo Clinic, Rochester, Minnesota
  • H. J. Gukasyan
    Pfizer Global R & D, San Diego, California
  • J. G. Arroyo
    Ophthalmology, Beth Israel Deaconess Med Ctr, Boston, Massachusetts
  • Footnotes
    Commercial Relationships  K.D. Kovacs, None; M.T. Quirk, None; O.M. Ceron, None; P.S. Silva, None; R.J. Singh, None; H.J. Gukasyan, None; J.G. Arroyo, None.
  • Footnotes
    Support  Macula Society Research Grant
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 2443. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      K. D. Kovacs, M. T. Quirk, O. M. Ceron, P. S. Silva, R. J. Singh, H. J. Gukasyan, J. G. Arroyo; Pharmacokinetic Study of Vitreous and Serum Concentrations of Triamcinolone Acetonide After Posterior Sub-Tenon’s Injection. Invest. Ophthalmol. Vis. Sci. 2010;51(13):2443.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose:
 

To compare a theoretical pharmacokinetic model of triamcinolone acetonide (TA) after posterior sub-Tenon’s (PST) injection with serum and undiluted vitreous TA concentrations obtained at the time of pars plana vitrectomy.

 
Methods:
 

This IRB-approved prospective, interventional study compared a theoretical model of TA diffusion after PST injection, constructed using diffusion coefficients from rabbit eyes, with TA levels in experimental undiluted vitreous and serum samples from 57 patients undergoing vitrectomy for macular hole or epiretinal membrane assessed via mass spectrometry and HPLC. At least five pairs of samples were collected at each of seven time points (1 day, 3 days, and 1, 2, 3, 4, and 8 weeks) after PST TA injection, with six controls who did not receive a steroid injection.

 
Results:
 

The theoretical model predicted that TA levels in systemic blood, vitreous and choroidal extracellular matrix would plateau after three days at 15 ng/mL, 227 ng/mL and 2230 ng/mL, respectively. Average vitreous levels of TA peaked at 111 ng/ml at day 1, then reached a plateau around 15-25 ng/mL. Average serum TA levels peaked at day 3 near 35 ng/mL, due largely to one sample with an elevated concentration, and ranged from 2-8 ng/mL at all other time points.

 
Conclusions:
 

The theoretical model predicts efficient delivery of TA from the PST space to the extracellular choroidal matrix. The experimental findings demonstrated low levels of TA in the serum and higher levels in the vitreous lasting at least one month. Both assessments support trans-scleral delivery of PST TA.  

 
Keywords: corticosteroids • injection • vitreous 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×